James T Dalton

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/4270466/publications.pdf

Version: 2024-02-01

168 papers	9,821 citations	31902 53 h-index	40881 93 g-index
177 all docs	177 docs citations	177 times ranked	9080 citing authors

#	Article	IF	Citations
1	Selective androgen receptor modulators activate the canonical prostate cancer androgen receptor program and repress cancer growth. Journal of Clinical Investigation, 2021, 131, .	3.9	23
2	Development of selective androgen receptor modulators (SARMs). Molecular and Cellular Endocrinology, 2018, 465, 134-142.	1.6	164
3	A Potent, Metabolically Stable Tubulin Inhibitor Targets the Colchicine Binding Site and Overcomes Taxane Resistance. Cancer Research, 2018, 78, 265-277.	0.4	91
4	Activity of VERU-111, an novel oral Î± and Î² tubulin inhibitor, against paclitaxel sensitive and resistant prostate cancer.. Journal of Clinical Oncology, 2018, 36, 302-302.	0.8	0
5	The long and winding road for selective androgen receptor modulators. British Journal of Clinical Pharmacology, 2017, 83, 2131-2133.	1.1	19
6	Novel Selective Agents for the Degradation of Androgen Receptor Variants to Treat Castration-Resistant Prostate Cancer. Cancer Research, 2017, 77, 6282-6298.	0.4	62
7	Pharmacologic activation of estrogen receptor Î± increases mitochondrial function, energy expenditure, and brown adipose tissue. FASEB Journal, 2017, 31, 266-281.	0.2	52
8	Androgen Receptor: A Complex Therapeutic Target for Breast Cancer. Cancers, 2016, 8, 108.	1.7	49
9	Pharmacokinetic drug interactions of the selective androgen receptor modulator GTx-024(Enobosarm) with itraconazole, rifampin, probenecid, celecoxib and rosuvastatin. Investigational New Drugs, 2016, 34, 458-467.	1.2	18
10	Study Design and Rationale for the Phase 3 Clinical Development Program of Enobosarm, a Selective Androgen Receptor Modulator, for the Prevention and Treatment of Muscle Wasting in Cancer Patients (POWER Trials). Current Oncology Reports, 2016, 18, 37.	1.8	128
11	Selective Estrogen Receptor Alpha Agonist GTx-758 Decreases Testosterone with Reduced Side Effects of Androgen Deprivation Therapy in Men with Advanced Prostate Cancer. European Urology, 2015, 67, 334-341.	0.9	15
12	Selective Estrogen Receptor Modulators (SERMs) and Selective Androgen Receptor Modulators (SARMs). , 2015, , 205-227.		0
13	TMPRSS2:ERG Gene Fusion Predicts Subsequent Detection of Prostate Cancer in Patients With High-Grade Prostatic Intraepithelial Neoplasia. Journal of Clinical Oncology, 2014, 32, 206-211.	0.8	90
14	Selective androgen receptor modulators as improved androgen therapy for advanced breast cancer. Steroids, 2014, 90, 94-100.	0.8	27
15	Design, Synthesis, and Biological Evaluation of Stable Colchicine Binding Site Tubulin Inhibitors as Potential Anticancer Agents. Journal of Medicinal Chemistry, 2014, 57, 7355-7366.	2.9	83
16	Effect of para halogen modification of S-3-(phenoxy)-2-hydroxy-2-methyl-N-(4-nitro-3-trifluoromethyl-phenyl)-propionamides on metabolism and clearance. Archives of Pharmacal Research, 2014, 37, 1464-1476.	2.7	2
17	Comparison of High-Dose Intermittent and Low-Dose Continuous Oral Artemisinin in Dogs With Naturally Occurring Tumors. Journal of the American Animal Hospital Association, 2014, 50, 390-395.	0.5	13
18	Selective Androgen Receptor Modulators (SARMs) Negatively Regulate Triple-Negative Breast Cancer Growth and Epithelial:Mesenchymal Stem Cell Signaling. PLoS ONE, 2014, 9, e103202.	1.1	57

#	Article	IF	Citations
19	Selective androgen receptor modulators for the treatment of late onset male hypogonadism. Asian Journal of Andrology, 2014, 16, 256.	0.8	16
20	Standard Pentostatin Dose Reductions in Renal Insufficiency Are Not Adequate: Selected Patients with Steroid-Refractory Acute Graft-Versus-Host Disease. Clinical Pharmacokinetics, 2013, 52, 705-712.	1.6	4
21	Absorption, distribution, metabolism and excretion of the novel SARM GTx-024 [(S)-N-(4-cyano-3-(trifluoromethyl)phenyl)-3-(4-cyanophenoxy)-2-hydroxy-2-methylpropanamide] in rats. Xenobiotica, 2013, 43, 993-1009.	0.5	13
22	Effects of enobosarm on muscle wasting and physical function in patients with cancer: a double-blind, randomised controlled phase 2 trial. Lancet Oncology, The, 2013, 14, 335-345.	5.1	301
23	Discovery of 4-Aryl-2-benzoyl-imidazoles as Tubulin Polymerization Inhibitor with Potent Antiproliferative Properties. Journal of Medicinal Chemistry, 2013, 56, 3318-3329.	2.9	55
24	Role and pharmacologic significance of cytochrome Pâ€450 2D6 in oxidative metabolism of toremifene and tamoxifen. International Journal of Cancer, 2013, 132, 1475-1485.	2.3	14
25	ERÎ² Selective Agonist Inhibits Angiotensin-Induced Cardiovascular Pathology in Female Mice. Endocrinology, 2013, 154, 4352-4364.	1.4	34
26	Selective androgen receptor modulators for the prevention and treatment of muscle wasting associated with cancer. Current Opinion in Supportive and Palliative Care, 2013, 7, 345-351.	0.5	72
27	Steroidogenic Enzyme AKR1C3 Is a Novel Androgen Receptor-Selective Coactivator that Promotes Prostate Cancer Growth. Clinical Cancer Research, 2013, 19, 5613-5625.	3.2	98
28	Estrogen regulates histone deacetylases to prevent cardiac hypertrophy. Molecular Biology of the Cell, 2013, 24, 3805-3818.	0.9	61
29	Discovery and Preclinical Characterization of Novel Small Molecule TRK and ROS1 Tyrosine Kinase Inhibitors for the Treatment of Cancer and Inflammation. PLoS ONE, 2013, 8, e83380.	1.1	19
30	Î²-LGND2, an ERÎ² Selective Agonist, Inhibits Pathologic Retinal Neovascularization. , 2012, 53, 5066.		11
31	Preclinical Characterization of a Novel Diphenyl Benzamide Selective ERÎ± Agonist for Hormone Therapy in Prostate Cancer. Endocrinology, 2012, 153, 1070-1081.	1.4	11
32	Pharmacokinetics, pharmacodynamics and metabolism of a novel anticancer agent for prostate cancer. International Journal of Oncology, 2012, 41, 337-44.	1.4	1
33	Novel Tubulin Polymerization Inhibitors Overcome Multidrug Resistance and Reduce Melanoma Lung Metastasis. Pharmaceutical Research, 2012, 29, 3040-3052.	1.7	50
34	Orally Bioavailable Tubulin Antagonists for Paclitaxel-Refractory Cancer. Pharmaceutical Research, 2012, 29, 3053-3063.	1.7	19
35	Androgen receptor antagonists: a patent review (2008 â€“ 2011). Expert Opinion on Therapeutic Patents, 2012, 22, 541-565.	2.4	22
36	Discovery of Novel 2-Aryl-4-benzoyl-imidazole (ABI-III) Analogues Targeting Tubulin Polymerization As Antiproliferative Agents. Journal of Medicinal Chemistry, 2012, 55, 7285-7289.	2.9	100

#	Article	IF	Citations
37	Alanine Aminotransferase Regulation by Androgens in Non-hepatic Tissues. Pharmaceutical Research, 2012, 29, 1046-1056.	1.7	12
38	Design, Synthesis, and SAR Studies of 4-Substituted Methoxylbenzoyl-aryl-thiazoles Analogues as Potent and Orally Bioavailable Anticancer Agents. Journal of Medicinal Chemistry, 2011, 54, 4678-4693.	2.9	99
39	Muscle Wasting in Cancer Cachexia: Clinical Implications, Diagnosis, and Emerging Treatment Strategies. Annual Review of Medicine, 2011, 62, 265-279.	5.0	268
40	Unexpected Binding Orientation of Bulky-B-Ring Anti-Androgens and Implications for Future Drug Targets. Journal of Medicinal Chemistry, 2011, 54, 3973-3976.	2.9	43
41	Cancer cachexia therapy: a key weapon in the fight against cancer. Current Opinion in Clinical Nutrition and Metabolic Care, 2011, 14, 268-273.	1.3	25
42	Pharmacokinetic Optimization of 4-Substituted Methoxybenzoyl-aryl-thiazole and 2-Aryl-4-benzoyl-imidazole for Improving Oral Bioavailability. Drug Metabolism and Disposition, 2011, 39, 1833-1839.	1.7	30
43	A novel bis-indole destabilizes microtubules and displays potent in vitro and in vivo antitumor activity in prostate cancer. Cancer Chemotherapy and Pharmacology, 2011, 67, 293-304.	1.1	20
44	The selective androgen receptor modulator GTxâ€024 (enobosarm) improves lean body mass and physical function in healthy elderly men and postmenopausal women: results of a doubleâ€blind, placeboâ€controlled phase II trial. Journal of Cachexia, Sarcopenia and Muscle, 2011, 2, 153-161.	2.9	304
45	Mass spectrometric characterization of urinary metabolites of the selective androgen receptor modulator Sâ€22 to identify potential targets for routine doping controls. Rapid Communications in Mass Spectrometry, 2011, 25, 2187-2195.	0.7	38
46	Synthesis and antiproliferative activity of novel 2-aryl-4-benzoyl-imidazole derivatives targeting tubulin polymerization. Bioorganic and Medicinal Chemistry, 2011, 19, 4782-4795.	1.4	64
47	Biotransformation of a Novel Antimitotic Agent, I-387, by Mouse, Rat, Dog, Monkey, and Human Liver Microsomes and In Vivo Pharmacokinetics in Mice. Drug Metabolism and Disposition, 2011, 39, 636-643.	1.7	8
48	Molecular Target Characterization and Antimyeloma Activity of the Novel, Insulin-like Growth Factor 1 Receptor Inhibitor, GTx-134. Clinical Cancer Research, 2011, 17, 4693-4704.	3.2	7
49	Biological Activity of 4-Substituted Methoxybenzoyl- Aryl-Thiazole: An Active Microtubule Inhibitor. Cancer Research, 2011, 71, 216-224.	0.4	32
50	Drug interaction potential of toremifene andN-desmethyltoremifene with multiple cytochrome P450 isoforms. Xenobiotica, 2011, 41, 851-862.	0.5	7
51	Characterization of in vitro generated metabolites of the selective androgen receptor modulators Sâ€22 and Sâ€23 and in vivo comparison to postâ€administration canine urine specimens. Drug Testing and Analysis, 2010, 2, 589-598.	1.6	41
52	Competitive mass spectrometry binding assay for characterization of three binding sites of tubulin. Journal of Mass Spectrometry, 2010, 45, 1160-1166.	0.7	22
53	Synthesis, in vitro structureâ€“activity relationship, and in vivo studies of 2-arylthiazolidine-4-carboxylic acid amides as anticancer agents. Bioorganic and Medicinal Chemistry, 2010, 18, 477-495.	1.4	35
54	Flavopiridol Pharmacogenetics: Clinical and Functional Evidence for the Role of SLCO1B1/OATP1B1 in Flavopiridol Disposition. PLoS ONE, 2010, 5, e13792.	1.1	45

#	Article	IF	Citations
55	GTx-822, an ERÎ²-Selective Agonist, Protects Retinal Pigment Epithelium (ARPE-19) from Oxidative Stress by Activating MAPK and PI3-K Pathways. , 2010, 51, 5934.		9
56	17-Î² Estradiol Protects ARPE-19 Cells from Oxidative Stress through Estrogen Receptor-Î². , 2010, 51, 5278.		46
57	Drug Metabolism and Pharmacokinetics of 4-Substituted Methoxybenzoyl-aryl-thiazoles. Drug Metabolism and Disposition, 2010, 38, 2032-2039.	1.7	16
58	Discovery and Mechanistic Characterization of a Novel Selective Nuclear Androgen Receptor Exporter for the Treatment of Prostate Cancer. Cancer Research, 2010, 70, 842-851.	0.4	24
59	Nonsteroidal Selective Androgen Receptor Modulators Enhance Female Sexual Motivation. Journal of Pharmacology and Experimental Therapeutics, 2010, 334, 439-448.	1.3	24
60	Estrogen Receptor-Î²-selective Ligands Alleviate High-fat Diet- and Ovariectomy-induced Obesity in Mice. Journal of Biological Chemistry, 2010, 285, 31292-31303.	1.6	109
61	FTY720 Shows Promising In vitro and In vivo Preclinical Activity by Downmodulating Cyclin D1 and Phospho-Akt in Mantle Cell Lymphoma. Clinical Cancer Research, 2010, 16, 3182-3192.	3.2	52
62	Discovery of Novel 2-Aryl-4-benzoyl-imidazoles Targeting the Colchicines Binding Site in Tubulin As Potential Anticancer Agents. Journal of Medicinal Chemistry, 2010, 53, 7414-7427.	2.9	111
63	Androgen Receptor. , 2010, , 143-182.		1
64	I-387, a Novel Antimitotic Indole, Displays a Potent In vitro and In vivo Antitumor Activity with Less Neurotoxicity. Molecular Cancer Therapeutics, 2010, 9, 2859-2868.	1.9	19
65	Estrogen receptor Î² selective nonsteroidal estrogens: seeking clinical indications. Expert Opinion on Therapeutic Patents, 2010, 20, 507-534.	2.4	25
66	Effects of a Novel Selective Androgen Receptor Modulator on Dexamethasone-Induced and Hypogonadism-Induced Muscle Atrophy. Endocrinology, 2010, 151, 3706-3719.	1.4	60
67	MicroRNAs Are Mediators of Androgen Action in Prostate and Muscle. PLoS ONE, 2010, 5, e13637.	1.1	52
68	Combination bortezomib and rituximab treatment affects multiple survival and death pathways to promote apoptosis in mantle cell lymphoma. MAbs, 2009, 1, 31-40.	2.6	33
69	A phase I/II dose escalation study of apolizumab (Hu1D10) using a stepped-up dosing schedule in patients with chronic lymphocytic leukemia and acute leukemia. Leukemia and Lymphoma, 2009, 50, 1958-1963.	0.6	32
70	Structure determination of chiral sulfoxide in diastereomeric bicalutamide derivatives. Chirality, 2009, 21, 578-583.	1.3	13
71	Effects of Selective Androgen Receptor Modulator (SARM) Treatment in Osteopenic Female Rats. Pharmaceutical Research, 2009, 26, 2471-2477.	1.7	26
72	A novel liposomal formulation of flavopiridol. International Journal of Pharmaceutics, 2009, 365, 170-174.	2.6	43

#	Article	IF	Citations
73	Nonsteroidal Selective Androgen Receptor Modulators (SARMs): Dissociating the Anabolic and Androgenic Activities of the Androgen Receptor for Therapeutic Benefit. Journal of Medicinal Chemistry, 2009, 52, 3597-3617.	2.9	191
74	Discovery of 4-Substituted Methoxybenzoyl-aryl-thiazole as Novel Anticancer Agents: Synthesis, Biological Evaluation, and Structureâ"Activity Relationships. Journal of Medicinal Chemistry, 2009, 52, 1701-1711.	2.9	162
75	Preclinical Characterization of a (S)-N-(4-Cyano-3-Trifluoromethyl-Phenyl)-3-(3-Fluoro,) Tj ETQq1 1 0.784314 rgBT /Overlock 10 Tf 50 667 Hormonal Male Contraception. Endocrinology, 2009, 150, 385-395.	1.4	48
76	Clinical response and pharmacokinetics from a phase 1 study of an active dosing schedule of flavopiridol in relapsed chronic lymphocytic leukemia. Blood, 2009, 113, 2637-2645.	0.6	152
77	FTY720 Demonstrates Promising in-Vitro and in-Vivo Pre-Clinical Activity by Down-Modulation of Cyclin D1 and Pakt in Mantle Cell Lymphoma.. Blood, 2009, 114, 3728-3728.	0.6	0
78	Development and validation of a sensitive liquid chromatography/mass spectrometry method for quantitation of flavopiridol in plasma enables accurate estimation of pharmacokinetic parameters with a clinically active dosing schedule. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2008, 868, 110-115.	1.2	16
79	Development and validation of a rapid and sensitive high-performance liquid chromatographyâ€"mass spectroscopy assay for determination of 17-(allylamino)-17-demethoxygeldanamycin and 17-(amino)-17-demethoxygeldanamycin in human plasma. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2008, 871, 15-21.	1.2	7
80	Synthesis and antiproliferative activity of imidazole and imidazoline analogs for melanoma. Bioorganic and Medicinal Chemistry Letters, 2008, 18, 3183-3187.	1.0	46
81	Effect of B-ring substitution pattern on binding mode of propionamide selective androgen receptor modulators. Bioorganic and Medicinal Chemistry Letters, 2008, 18, 5567-5570.	1.0	41
82	Inhibitors of Tubulin Assembly Identified through Screening a Compound Library. Chemical Biology and Drug Design, 2008, 72, 513-524.	1.5	22
83	Steroidal Androgens and Nonsteroidal, Tissue-Selective Androgen Receptor Modulator, S-22, Regulate Androgen Receptor Function through Distinct Genomic and Nongenomic Signaling Pathways. Molecular Endocrinology, 2008, 22, 2448-2465.	3.7	65
84	FTY720 demonstrates promising preclinical activity for chronic lymphocytic leukemia and lymphoblastic leukemia/lymphoma. Blood, 2008, 111, 275-284.	0.6	137
85	Development and Validation of a Highly Sensitive Liquid Chromatography/Mass Spectrometry Method for Simultaneous Quantification of Lenalidomide and Flavopiridol in Human Plasma. Therapeutic Drug Monitoring, 2008, 30, 620-627.	1.0	27
86	Selective androgen receptor modulators in preclinical and clinical development. Nuclear Receptor Signaling, 2008, 6, nrs.06010.	1.0	129
87	A bifunctional colchicinoid that binds to the androgen receptor. Molecular Cancer Therapeutics, 2007, 6, 2328-2336.	1.9	14
88	Crystal Structure of the T877A Human Androgen Receptor Ligand-binding Domain Complexed to Cyproterone Acetate Provides Insight for Ligand-induced Conformational Changes and Structure-based Drug Design. Journal of Biological Chemistry, 2007, 282, 13648-13655.	1.6	107
89	Flavopiridol administered using a pharmacologically derived schedule is associated with marked clinical efficacy in refractory, genetically high-risk chronic lymphocytic leukemia. Blood, 2007, 109, 399-404.	0.6	367
90	Population Pharmacokinetics of Humanized Monoclonal Antibody HuCC49Î"CH2 and Murine Antibody CC49 in Colorectal Cancer Patients. Journal of Clinical Pharmacology, 2007, 47, 227-237.	1.0	27

#	Article	IF	Citations
91	Flavopiridol in Chronic Lymphocytic Leukemia. Clinical Leukemia, 2007, 1, 292-297.	0.2	4
92	Ockham's Razor and Selective Androgen Receptor Modulators (SARMs): Are We Overlooking the Role of 5Â-Reductase?. Molecular Interventions: Pharmacological Perspectives From Biology, Chemistry and Genomics, 2007, 7, 10-13.	3.4	46
93	Synthesis and antiproliferative activity of thiazolidine analogs for melanoma. Bioorganic and Medicinal Chemistry Letters, 2007, 17, 4113-4117.	1.0	66
94	Expanding the therapeutic use of androgens via selective androgen receptor modulators (SARMs). Drug Discovery Today, 2007, 12, 241-248.	3.2	192
95	Selective Androgen Receptor Modulator (SARM) Treatment Prevents Bone Loss and Reduces Body Fat in Ovariectomized Rats. Pharmaceutical Research, 2007, 24, 328-335.	1.7	98
96	Preliminary Results of a Phase II Study of Flavopiridol (Alvocidib) in Relapsed Chronic Lymphocytic Leukemia (CLL): Confirmation of Clinical Activity in High-Risk Patients and Achievement of Complete Responses (CR).. Blood, 2007, 110, 3104-3104.	0.6	3
97	Structure-activity relationship studies of arylthiazolidine amides as selective cytotoxic agents for melanoma. Anticancer Research, 2007, 27, 883-8.	0.5	21
98	Therapeutic potential of the SARMs: revisiting the androgen receptor for drug discovery. Expert Opinion on Investigational Drugs, 2006, 15, 377-387.	1.9	39
99	Drug Insight: testosterone and selective androgen receptor modulators as anabolic therapies for chronic illness and aging. Nature Clinical Practice Endocrinology and Metabolism, 2006, 2, 146-159.	2.9	272
100	PHARMACOKINETICS AND METABOLISM OF A SELECTIVE ANDROGEN RECEPTOR MODULATOR IN RATS: IMPLICATION OF MOLECULAR PROPERTIES AND INTENSIVE METABOLIC PROFILE TO INVESTIGATE IDEAL PHARMACOKINETIC CHARACTERISTICS OF A PROPANAMIDE IN PRECLINICAL STUDY. Drug Metabolism and Disposition, 2006, 34, 483-494.	1.7	31
101	Synthesis, Calpain Inhibitory Activity, and Cytotoxicity of P2-Substituted Proline and Thiaproline Peptidyl Aldehydes and Peptidyl Î±-Ketoamides. Journal of Medicinal Chemistry, 2006, 49, 5282-5290.	2.9	17
102	INTERSPECIES DIFFERENCES IN PHARMACOKINETICS AND METABOLISM OF S-3-(4-ACETYLAMINO-PHENOXY)-2-HYDROXY-2-METHYL-N-(4-NITRO-3-TRIFLUOROMETHYLPHENYL)-PROPIONAMIDE: THE ROLE OF N-ACETYLTRANSFERASE. Drug Metabolism and Disposition, 2006, 34, 254-260.	1.7	20
103	Pre-systemic metabolism prevents in vivo antikinetoplastid activity of N1,N4-substituted 3,5-dinitro sulfanilamide, GB-II-150. Life Sciences, 2006, 79, 1081-1093.	2.0	11
104	Antikinetoplastid antimitotic activity and metabolic stability of dinitroaniline sulfonamides and benzamides. Bioorganic and Medicinal Chemistry, 2006, 14, 5699-5710.	1.4	20
105	Arylisothiocyanato selective androgen receptor modulators (SARMs) for prostate cancer. Bioorganic and Medicinal Chemistry, 2006, 14, 6525-6538.	1.4	29
106	Synthesis of oxazolidinedione derived bicalutamide analogs. Tetrahedron Letters, 2006, 47, 3953-3955.	0.7	9
107	Cesium fluoride and tetra-n-butylammonium fluoride mediated 1,4-Nâ†'O shift of disubstituted phenyl ring of a bicalutamide derivative. Tetrahedron Letters, 2006, 47, 3941-3944.	0.7	14
108	Pharmacokinetics and Pharmacodynamics of Nonsteroidal Androgen Receptor Ligands. Pharmaceutical Research, 2006, 23, 1641-1658.	1.7	92

#	Article	IF	Citations
109	Toremifene â€“ a promising therapy for the prevention of prostate cancer and complications of androgen deprivation therapy. Expert Opinion on Investigational Drugs, 2006, 15, 293-305.	1.9	22
110	Preclinical Pharmacology of a Nonsteroidal Ligand for Androgen Receptor-Mediated Imaging of Prostate Cancer. Journal of Pharmacology and Experimental Therapeutics, 2006, 317, 402-408.	1.3	8
111	CHARACTERIZATION OF THE IN VITRO METABOLISM OF SELECTIVE ANDROGEN RECEPTOR MODULATOR USING HUMAN, RAT, AND DOG LIVER ENZYME PREPARATIONS. Drug Metabolism and Disposition, 2006, 34, 243-253.	1.7	30
112	Domain Structure and DNA Binding Regions of Î² Protein from Bacteriophage Î». Journal of Biological Chemistry, 2006, 281, 25205-25214.	1.6	18
113	In Vivo Metabolism and Final Disposition of a Novel Nonsteroidal Androgen in Rats and Dogs. Drug Metabolism and Disposition, 2006, 34, 1713-1721.	1.7	18
114	Flavopiridol Can Be Safely Dose Escalated in Relapsed CLL Patients: Achievement of Target Cmax Results in Improved Clinical Activity.. Blood, 2006, 108, 2845-2845.	0.6	4
115	Updated Results of a Phase I Study of Flavopiridol in Acute Leukemias Using a Novel, Pharmacokinetically Derived Schedule: Clinical Activity Including Hyperacute Tumor Lysis Syndrome (TLS), Pharmacokinetics (PK), and Pharmacodynamics (PD).. Blood, 2006, 108, 4578-4578.	0.6	0
116	FTY720 (2-Amino-2-[2-(4-octylphenyl) ethyl] Propane 1, 3-diol hydrochloride), Mediates Cytotoxicity through Caspase Independent and Protein Phosphatase 2A Dependent Mechanisms in Chronic Lymphocytic Leukemia and Lymphoblastic Leukemia/Lymphoma.. Blood, 2006, 108, 2095-2095.	0.6	16
117	Synthesis of irreversibly binding bicalutamide analogs for imaging studies. Tetrahedron Letters, 2005, 46, 4821-4823.	0.7	11
118	SAR studies of 2-arylthiazolidine-4-carboxylic acid amides: A novel class of cytotoxic agents for prostate cancer. Bioorganic and Medicinal Chemistry Letters, 2005, 15, 4010-4013.	1.0	20
119	Synthesis and Antiproliferative Activity of 2-Aryl-4-oxo-thiazolidin-3-yl-amides for Prostate Cancer.. ChemInform, 2005, 36, no.	0.1	0
120	Chemistry and Structural Biology of Androgen Receptor. ChemInform, 2005, 36, no.	0.1	0
121	Discovery and Therapeutic Promise of Selective Androgen Receptor Modulators. Molecular Interventions: Pharmacological Perspectives From Biology, Chemistry and Genomics, 2005, 5, 173-188.	3.4	115
122	The Para Substituent of S-3-(Phenoxy)-2-hydroxy-2-methyl-N-(4-nitro-3-trifluoromethyl-phenyl)-propionamides Is a Major Structural Determinant of in Vivo Disposition and Activity of Selective Androgen Receptor Modulators. Journal of Pharmacology and Experimental Therapeutics, 2005, 315, 230-239.	1.3	67
123	In Vitroandin VivoStructure-Activity Relationships of Novel Androgen Receptor Ligands with Multiple Substituents in the B-Ring. Endocrinology, 2005, 146, 5444-5454.	1.4	22
124	Selective Androgen Receptor Modulator Treatment Improves Muscle Strength and Body Composition and Prevents Bone Loss in Orchidectomized Rats. Endocrinology, 2005, 146, 4887-4897.	1.4	173
125	Structural Basis for Accommodation of Nonsteroidal Ligands in the Androgen Receptor. Journal of Biological Chemistry, 2005, 280, 37747-37754.	1.6	186
126	Structural basis for antagonism and resistance of bicalutamide in prostate cancer. Proceedings of the National Academy of Sciences of the United States of America, 2005, 102, 6201-6206.	3.3	367

#	Article	IF	Citations
127	A Selective Androgen Receptor Modulator for Hormonal Male Contraception. Journal of Pharmacology and Experimental Therapeutics, 2005, 312, 546-553.	1.3	82
128	Chemistry and Structural Biology of Androgen Receptor. Chemical Reviews, 2005, 105, 3352-3370.	23.0	439
129	Discovery of 2-Arylthiazolidine-4-carboxylic Acid Amides as a New Class of Cytotoxic Agents for Prostate Cancerâ€. Journal of Medicinal Chemistry, 2005, 48, 2584-2588.	2.9	97
130	Pharmacokinetics ofS-3-(4-acetylamino-phenoxy)-2-hydroxy-2-methyl-N-(4-nitro-) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 627 Td (3-trifluor modulator. Xenobiotica, 2004, 34, 273-280.	0.5	35
131	Efficient Microwave Enhanced Synthesis of 4-Thiazolidinones. Synlett, 2004, 2004, 2357-2358.	1.0	4
132	Comparison of the Pharmacological Effects of a Novel Selective Androgen Receptor Modulator, the 5Î±-Reductase Inhibitor Finasteride, and the Antiandrogen Hydroxyflutamide in Intact Rats: New Approach for Benign Prostate Hyperplasia. Endocrinology, 2004, 145, 5420-5428.	1.4	109
133	Tip110, the Human Immunodeficiency Virus Type 1 (HIV-1) Tat-interacting Protein of 110 kDa as a Negative Regulator of Androgen Receptor (AR) Transcriptional Activation. Journal of Biological Chemistry, 2004, 279, 21766-21773.	1.6	26
134	Synthesis of novel iodo derived bicalutamide analogs. Tetrahedron Letters, 2004, 45, 9475-9477.	0.7	20
135	Synthesis and biological evaluation of novel cytotoxic phospholipids for prostate cancer. Bioorganic and Medicinal Chemistry Letters, 2004, 14, 4919-4923.	1.0	17
136	Synthesis and antiproliferative activity of 2-aryl-4-oxo-thiazolidin-3-yl-amides for prostate cancer. Bioorganic and Medicinal Chemistry Letters, 2004, 14, 5289-5293.	1.0	117
137	Favorable Effects of Weak Acids on Negative-Ion Electrospray Ionization Mass Spectrometry. Analytical Chemistry, 2004, 76, 839-847.	3.2	182
138	A Ligand-Based Approach To Identify Quantitative Structureâ^'Activity Relationships for the Androgen Receptor. Journal of Medicinal Chemistry, 2004, 47, 3765-3776.	2.9	71
139	Design, Synthesis, and Biological Characterization of Metabolically Stable Selective Androgen Receptor Modulators. Journal of Medicinal Chemistry, 2004, 47, 993-998.	2.9	132
140	Flavopiridol Administered as a Pharmacologically-Derived Schedule Demonstrates Marked Clinical Activity in Refractory, Genetically High Risk, Chronic Lymphocytic Leukemia (CLL).. Blood, 2004, 104, 341-341.	0.6	17
141	Structural Determinants of P-Glycoprotein-Mediated Transport of Glucocorticoids. Pharmaceutical Research, 2003, 20, 1794-1803.	1.7	112
142	Pharmacodynamics of Selective Androgen Receptor Modulators. Journal of Pharmacology and Experimental Therapeutics, 2003, 304, 1334-1340.	1.3	140
143	Pharmacology, Pharmacokinetics, and Metabolism of Acetothiolutamide, a Novel Nonsteroidal Agonist for the Androgen Receptor. Journal of Pharmacology and Experimental Therapeutics, 2003, 304, 1323-1333.	1.3	42
144	Key Structural Features of Nonsteroidal Ligands for Binding and Activation of the Androgen Receptor. Molecular Pharmacology, 2003, 63, 211-223.	1.0	103

#	Article	IF	Citations
145	Clinical Pharmacokinetics of 5-Aminolevulinic Acid in Healthy Volunteers and Patients at High Risk for Recurrent Bladder Cancer. Journal of Pharmacology and Experimental Therapeutics, 2002, 301, 507-512.	1.3	68
146	Novel nonsteroidal ligands with high binding affinity and potent functional activity for the androgen receptor. European Journal of Medicinal Chemistry, 2002, 37, 619-634.	2.6	60
147	Homology Modeling Using Multiple Molecular Dynamics Simulations and Docking Studies of the Human Androgen Receptor Ligand Binding Domain Bound to Testosterone and Nonsteroidal Ligandsâ€. Journal of Medicinal Chemistry, 2001, 44, 1729-1740.	2.9	90
148	Recombinant Expression and Purification of Human Androgen Receptor in a Baculovirus System. Biochemical and Biophysical Research Communications, 2001, 284, 828-835.	1.0	8
149	Identification of a Novel Phosphorylation Site in Human Androgen Receptor by Mass Spectrometry. Biochemical and Biophysical Research Communications, 2001, 284, 836-844.	1.0	33
150	Mass Spectrometric Characterization of the Human Androgen Receptor Ligand-Binding Domain Expressed in Escherichia coli. Biochemistry, 2001, 40, 10756-10763.	1.2	8
151	Time-Variant Increase in Methylprednisolone Clearance in Patients with Acute Respiratory Distress Syndrome: A Population Pharmacokinetic Study. Journal of Clinical Pharmacology, 2001, 41, 415-424.	1.0	21
152	Predictive ability of level A in vitro-in vivo correlation for ringcap controlled-release acetaminophen tablets. Pharmaceutical Research, 2001, 18, 1729-1734.	1.7	19
153	Creation of polarized cells coexpressing CYP3A4, NADPH cytochrome P450 reductase and MDR1/P-glycoprotein. Pharmaceutical Research, 2000, 17, 803-810.	1.7	33
154	Cytochrome P-450 2C9 Sensitizes Human Prostate Tumor Cells to Cyclophosphamide via a Bystander Effect. Antimicrobial Agents and Chemotherapy, 2000, 44, 2659-2663.	1.4	11
155	Chiral Nonsteroidal Affinity Ligands for the Androgen Receptor. 1. Bicalutamide Analogues Bearing Electrophilic Groups in the B Aromatic Ring1. Journal of Medicinal Chemistry, 2000, 43, 581-590.	2.9	62
156	Use of Intravenous Valproate in Three Pediatric Patients with Nonconvulsive or Convulsive Status Epilepticus. Annals of Pharmacotherapy, 1999, 33, 579-584.	0.9	47
157	Pharmacokinetics of aminolevulinic acid after intravesical administration to dogs. Pharmaceutical Research, 1999, 16, 288-295.	1.7	5
158	Affinity labeling of the androgen receptor with nonsteroidal chemoaffinity ligands. Biochemical Pharmacology, 1999, 58, 1259-1267.	2.0	23
159	Discovery of Nonsteroidal Androgens. Biochemical and Biophysical Research Communications, 1998, 244, 1-4.	1.0	211
160	Medetomidine Analogs as Î±2-Adrenergic Ligands. 3. Synthesis and Biological Evaluation of a New Series of Medetomidine Analogs and Their Potential Binding Interactions with Î±2-Adrenoceptors Involving a â€œMethyl Pocketâ€• Journal of Medicinal Chemistry, 1997, 40, 3014-3024.	2.9	16
161	Medetomidine Analogs as Î±2-Adrenergic Ligands. 2. Design, Synthesis, and Biological Activity of Conformationally Restricted Naphthalene Derivatives of Medetomidine. Journal of Medicinal Chemistry, 1996, 39, 3001-3013.	2.9	16
162	Comparative lipoprotein metabolism of myristate, palmitate, and stearate in normolipidemic men. Metabolism: Clinical and Experimental, 1996, 45, 1108-1118.	1.5	28

#	Article	IF	Citations
163	Pentamidine congeners. 4. DNA binding affinity and anti-Pneumocystis carinii activity of butamidine analogues. Bioorganic and Medicinal Chemistry Letters, 1996, 6, 1967-1970.	1.0	9
164	Pharmacology of N,N-di(n-butyl)adriamycin-14-valerate in the rat. Cancer Chemotherapy and Pharmacology, 1996, 37, 472-478.	1.1	3
165	Effects of bladder resorption on pharmacokinetic data analysis. Journal of Pharmacokinetics and Pharmacodynamics, 1994, 22, 183-205.	0.6	10
166	High-performance liquid chromatographic determination of pentamidine in plasma. Biomedical Applications, 1993, 622, 255-261.	1.7	7
167	A method to study drug concentration-depth profiles in tissues: mitomycin C in dog bladder wall. Pharmaceutical Research, 1991, 08, 168-173.	1.7	25
168	High-performance liquid chromatographic determination of mitomycin C in rat and human plasma and urine. Biomedical Applications, 1989, 495, 330-337.	1.7	9